SEC Comment Letter 0000000000-24-004299 to Acrivon Therapeutics, Inc. (ACRV) (CIK 0001781174) (ACRV)
Acrivon Therapeutics, Inc. (ACRV) (CIK 0001781174)
Date: April 19, 2024 · CIK: 0001781174 · Accession: 0000000000-24-004299
AI Filing Summary & Sentiment
File numbers found in text: 333-278761
Letter
United States securities and exchange commission logo April 19, 2024 Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer and President Acrivon Therapeutics, Inc. 480 Arsenal Way, Suite 100 Watertown, Massachusetts 02472 Re:Acrivon Therapeutics, Inc. Registration Statement on Form S-3 Filed April 17, 2024 File No. 333-278761 Dear Peter Blume-Jensen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nick DeAngelis, Esq.
Show Raw Text
United States securities and exchange commission logo
April 19, 2024
Peter Blume-Jensen, M.D., Ph.D.
Chief Executive Officer and President
Acrivon Therapeutics, Inc.
480 Arsenal Way, Suite 100
Watertown, Massachusetts 02472
Re:Acrivon Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 17, 2024
File No. 333-278761
Dear Peter Blume-Jensen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Nick DeAngelis, Esq.